Based on the level of Blimp-1 mRNA expression on T cells, we defined high-Blimp-1 (Blimp-1 ≥49.8% of CD4+ T cells, ≥35.4% of CD8+ T cells) vs. low-Blimp-1 (Blimp-1 <49.8% of CD4+ T cells, <35.4% of CD8+ T cells) subgroups in AML patients. Here, PRDM1 is linked to acute myeloid leukemia.